Guo YT - Search Results

1

[Research progress on human acute leukemia xenograft mouse models].

Guo YT, Li J, Ouyang J. Guo YT, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Apr;22(2):555-9. doi: 10.7534/j.issn.1009-2137.2014.02.054. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014. PMID: 24763042 Review. Chinese.

2

[The Effects of Decitabine Combined with All-Trans Retinoic Acid on the Number of Immune Cells in Myeloid Neoplasms].

Wei W, Liu Y, Shang LM, Cao Y, Wang F, Guo YT, Lin RR, Lin Y, Dong WM, Gu WY. Wei W, et al. Among authors: guo yt. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Feb;30(1):6-11. doi: 10.19746/j.cnki.issn.1009-2137.2022.01.002. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022. PMID: 35123596 Chinese.

3

[Survival and Prognosis of Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes Transformed from Myelodysplastic Syndrome].

Shang LM, Chen HJ, Liu Y, Cao Y, Li F, Guo YT, Dong WM, Lin Y, Gu WY. Shang LM, et al. Among authors: guo yt. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Apr;32(2):347-354. doi: 10.19746/j.cnki.issn.1009-2137.2024.02.004. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024. PMID: 38660835 Chinese.

4

[The Clinical Value of Neutrophil CD64 Index in Hematological Malignancies with Pulmonary Infection].

Xu Y, Dong WM, Lin Y, Guo YT, Liu J, Xu T, Gu WY. Xu Y, et al. Among authors: guo yt. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Oct;30(5):1601-1606. doi: 10.19746/j.cnki.issn.1009-2137.2022.05.047. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022. PMID: 36208273 Chinese.

5

[Efficacy Analysis of Bendamustine-Based Combination Regimen in Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma].

Guo YT, Li F, Dong WM, Lin Y, Xie XB, Ling Y, Yan F, Hua XY, He B, Gu WY. Guo YT, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Dec;30(6):1766-1771. doi: 10.19746/j.cnki.issn.1009-2137.2022.06.021. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022. PMID: 36476901 Chinese.

6

Overexpression of miR-17 predicts adverse prognosis and disease recurrence for acute myeloid leukemia.

Cao Y, Liu Y, Shang L, Chen H, Yue Y, Dong W, Guo Y, Yang H, Yang X, Liu Y, Gu W, Zhang X. Cao Y, et al. Int J Clin Oncol. 2022 Jul;27(7):1222-1232. doi: 10.1007/s10147-022-02161-5. Epub 2022 May 10. Int J Clin Oncol. 2022. PMID: 35536524 Free PMC article.

7

Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.

Yue Y, Wei W, Guo Y, Wang F, Dong W, Liu Y, Lin Y, Cao Y, Gu W. Yue Y, et al. Am J Case Rep. 2020 Oct 6;21:e925151. doi: 10.12659/AJCR.925151. Am J Case Rep. 2020. PMID: 33021971 Free PMC article. Review.

8

Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy.

Yue Y, Cao Y, Wang F, Zhang N, Qi Z, Mao X, Guo S, Li F, Guo Y, Lin Y, Dong W, Huang Y, Gu W. Yue Y, et al. Leuk Res. 2022 Nov;122:106949. doi: 10.1016/j.leukres.2022.106949. Epub 2022 Sep 6. Leuk Res. 2022. PMID: 36113267 Free article.

9

Chronic Myelomonocytic Leukemia following Multicentric Castleman Disease.

Li F, Zhang X, Guo Y, Zhu Y, Wu Y, Ling Y. Li F, et al. Case Rep Hematol. 2018 Jan 23;2018:5895903. doi: 10.1155/2018/5895903. eCollection 2018. Case Rep Hematol. 2018. PMID: 29607228 Free PMC article.

10

Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance.

Yue Y, Cao Y, Mao X, Wang F, Fan P, Qian L, Guo S, Li F, Guo Y, Chen T, Lin Y, Dong W, Liu Y, Huang Y, Gu W. Yue Y, et al. Front Oncol. 2022 Aug 5;12:894279. doi: 10.3389/fonc.2022.894279. eCollection 2022. Front Oncol. 2022. PMID: 35992875 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

169 results

Search Page

Filters